Close Menu
Advertisement
Subscribe
[the_ad id="32629"]
Acute Lymphoblastic Leukemia

Novel investigational agents for crizotinib resistant ALK-positive NSCLC.

Editor By No Comments1 Min Read

DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver discusses the novel investigational agents for crizotinib resistant ALK-positive NSCLC.

Share.

Related Posts